logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

FDA approves alpelisib for advanced or metastatic breast cancer

Common adverse events associated with the PI3K inhibitor include hyperglycemia and severe skin reactions.